ArticlePostepy dermatologii i alergologii2025
Effectiveness of direct immunofluorescence for diagnosing autoimmune bullous diseases: data from the Central European referral department.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Update on Pemphigus Vulgaris in Pregnancy and Neonates: Management Options and Our Clinical-Laboratory Experience.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autoimmune bullous disorders (AIBD) are a heterogeneous group of diseases resulting from autoantibodies production. Nowadays, direct immunofluorescence (DIF) is the basic diagnostic tool for diagnosing AIBD. Aim: This study was performed to assess the percentages of positive and negative DIF tests performed in individuals clinically suspected to suffer from AIBD in a single Central European referral department laboratory and to propose ways to improve the effectiveness of DIF in AIBD imaging diagnostics. Material and methods: A total of 1985 consecutive tests were collected during 9 consecutive years (2016-2024). We analysed the total number of results, the percentages of positive and negative results year by year, and according to the unit that sent material for testing. Results: We found that almost one-third of the tests were positive (30.88% overall, over 9 years). The percentage of positive results has varied from year to year (from 26.22% in 2016 to 38.89% in 2023). The percentage of positive results was higher in outpatient clinics than in hospital wards (33.7% vs. 22.9%; Conclusions: DIF should be performed thoughtfully at both clinical and laboratory levels, and approximately 31% of positive results should be regarded as a good outcome. To increase this percentage, specialised units should be maintained to keep up with the constant development of knowledge and experience in AIBD. Negative DIF results could also be useful in differential diagnostics of AIBD, but their percentage should be minimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.